{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:05:24Z","timestamp":1767985524843,"version":"3.49.0"},"posted":{"date-parts":[[2026,1,8]]},"group-title":"Pharmacology and Therapeutics","reference-count":67,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Angioedema is a life-threatening adverse drug reaction associated with renin-angiotensin-aldosterone system (RAAS) inhibitors, characterized by localized swelling in the deep layers of the skin. Well-established evidence indicates an up to fivefold higher incidence of RAAS inhibitor-induced angioedema in self-identified Black patients compared to White patients. The mechanisms underlying this health disparity remain poorly understood and are often attributed to race, a poor proxy for interindividual genetic similarity and social stressors. Here, we investigate the genetic and social determinants of RAAS inhibitor-induced angioedema as well as the etiology of this racial difference. In particular, we (1) discovered\n                  <jats:italic>OTULINL<\/jats:italic>\n                  and\n                  <jats:italic>CRABP1<\/jats:italic>\n                  as novel loci for RAAS inhibitor-induced angioedema, (2) confirmed the importance of bradykinin for this adverse drug reaction, (3) reported the first significant genome-wide association in self-identified Black participants, (4) identified alcohol use as an important social determinant, (5) demonstrated the strong role of variants enriched in 1000 Genomes African superpopulation-like genomes as the driver of racially differential angioedema risk, and (6) demonstrated the combined role of polygenic effect size and allele frequency differences in explaining these racial differences. Our results suggest that a clinical precision medicine tool may more precisely predict for whom RAAS inhibitors should be avoided (to prevent angioedema) compared to using race. These findings ultimately underscore the value of an evidence-based approach to removing race from treatment guidelines, which carries less potential harm than other removal strategies.\n                <\/jats:p>","DOI":"10.64898\/2026.01.06.26343530","type":"posted-content","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T21:10:18Z","timestamp":1767906618000},"source":"Crossref","is-referenced-by-count":0,"title":["Genetic and Social Determinants of Renin-Angiotensin-Aldosterone System Inhibitor-Induced Angioedema: A Precision Medicine Health Equity Study"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7774-8178","authenticated-orcid":false,"given":"Nanase","family":"Toda","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5425-1230","authenticated-orcid":false,"given":"Tanushree","family":"Haldar","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig C.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglei","family":"Hu","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Danilov","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Huntsman","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Lu","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California Division of Research, Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip S.","family":"Tsao","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA"},{"name":"Palo Alto VA Healthcare System, Palo Alto, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9559-4339","authenticated-orcid":false,"given":"Catherine","family":"Tcheandjieu","sequence":"additional","affiliation":[{"name":"Palo Alto VA Healthcare System, Palo Alto, CA, USA"},{"name":"Gladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA"},{"name":"Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Iribarren","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northern California Division of Research, Pleasanton, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bress","sequence":"additional","affiliation":[{"name":"Division of Health System Innovation and Research, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0108-2127","authenticated-orcid":false,"given":"Julie A.","family":"Lynch","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure (VINCI), VA Salt Lake City Health Care System, Salt Lake City, UT, USA"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elad","family":"Ziv","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA"},{"name":"Institute of Human Genetics, University of California San Francisco, San Francisco, CA, USA"},{"name":"Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5897-5543","authenticated-orcid":false,"given":"Akinyemi","family":"Oni-Orisan","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, USA"},{"name":"Institute of Human Genetics, University of California San Francisco, San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2026010906200670000_2026.01.06.26343530v1.1","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40256-023-00605-5","article-title":"The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines","volume":"23","year":"2023","journal-title":"Am. J. Cardiovasc. Drugs Drugs Devices Interv"},{"key":"2026010906200670000_2026.01.06.26343530v1.2","unstructured":"Marcum, Z. A. , Cohen, J. B. , Larson, E. B. , Williamson, J. & Bress, A. P. Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity? NAM Perspect. 2022, (2022)."},{"key":"2026010906200670000_2026.01.06.26343530v1.3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pcad.2016.10.002","article-title":"Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?","volume":"59","year":"2016","journal-title":"Prog. Cardiovasc. Dis"},{"key":"2026010906200670000_2026.01.06.26343530v1.4","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/pds.5361","article-title":"Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy","volume":"30","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"2026010906200670000_2026.01.06.26343530v1.5","first-page":"1624","article-title":"Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors","volume":"51","year":"2008","journal-title":"Hypertens. Dallas Tex 1979"},{"key":"2026010906200670000_2026.01.06.26343530v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90161-7"},{"key":"2026010906200670000_2026.01.06.26343530v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.03.034"},{"key":"2026010906200670000_2026.01.06.26343530v1.8","doi-asserted-by":"publisher","DOI":"10.2105\/ajph.2018.304883"},{"key":"2026010906200670000_2026.01.06.26343530v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2010.04.004"},{"key":"2026010906200670000_2026.01.06.26343530v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"2026010906200670000_2026.01.06.26343530v1.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"2026010906200670000_2026.01.06.26343530v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.02.010"},{"key":"2026010906200670000_2026.01.06.26343530v1.13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0003"},{"key":"2026010906200670000_2026.01.06.26343530v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMms2031080"},{"key":"2026010906200670000_2026.01.06.26343530v1.15","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaci.2023.11.921","article-title":"Meta-analysis of ACE inhibitor-induced angioedema identifies novel risk locus","volume":"153","year":"2024","journal-title":"J. Allergy Clin. Immunol"},{"key":"2026010906200670000_2026.01.06.26343530v1.16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2021.05.054","article-title":"Association of Variants Near the Bradykinin Receptor B2 Gene With Angioedema in Patients Taking ACE Inhibitors","volume":"78","year":"2021","journal-title":"J. Am. Coll. Cardiol"},{"key":"2026010906200670000_2026.01.06.26343530v1.17","doi-asserted-by":"crossref","first-page":"100464","DOI":"10.1016\/j.jacig.2025.100464","article-title":"A GWAS of angiotensin-converting enzyme inhibitor-induced angioedema in a South African population","volume":"4","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob"},{"key":"2026010906200670000_2026.01.06.26343530v1.18","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41397-020-0165-2","article-title":"Genome-wide association study of angioedema induced by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment","volume":"20","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"2026010906200670000_2026.01.06.26343530v1.19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cpt.2890","article-title":"Advancing CYP2D6 Pharmacogenetics through a Pharmacoequity Lens","volume":"114","year":"2023","journal-title":"Clin. Pharmacol. Ther"},{"key":"2026010906200670000_2026.01.06.26343530v1.20","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cpt.3736","article-title":"Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges","volume":"118","year":"2025","journal-title":"Clin. Pharmacol. Ther"},{"key":"2026010906200670000_2026.01.06.26343530v1.21","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06957-x"},{"key":"2026010906200670000_2026.01.06.26343530v1.22","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.115.178616"},{"key":"2026010906200670000_2026.01.06.26343530v1.23","first-page":"1476402","article-title":"Assessment of 105 Patients with Angiotensin Converting Enzyme-Inhibitor Induced Angioedema","volume":"2017","year":"2017","journal-title":"Int. J. Otolaryngol"},{"key":"2026010906200670000_2026.01.06.26343530v1.24","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.13090","article-title":"Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink","volume":"82","year":"2016","journal-title":"Br. J. Clin. Pharmacol"},{"key":"2026010906200670000_2026.01.06.26343530v1.25","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1637"},{"key":"2026010906200670000_2026.01.06.26343530v1.26","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/lary.24777","article-title":"Risk factors associated with severe and recurrent angioedema: an epidemic linked to ACE-inhibitors","volume":"124","year":"2014","journal-title":"The Laryngoscope"},{"key":"2026010906200670000_2026.01.06.26343530v1.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00982-8"},{"key":"2026010906200670000_2026.01.06.26343530v1.28","first-page":"1000","article-title":"FAM105A\/OTULINL Is a Pseudodeubiquitinase of the OTU-Class that Localizes to the ER Membrane","volume":"27","year":"2019","journal-title":"Struct. Lond. Engl. 1993"},{"key":"2026010906200670000_2026.01.06.26343530v1.29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.it.2021.05.003","article-title":"OTULIN in NF-\u03baB signaling, cell death, and disease","volume":"42","year":"2021","journal-title":"Trends Immunol"},{"key":"2026010906200670000_2026.01.06.26343530v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.07.019"},{"key":"2026010906200670000_2026.01.06.26343530v1.31","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1093\/rheumatology\/keaf428","article-title":"Long-term clinical course and treatment response in two patients with OTULIN-related autoinflammatory syndrome","volume":"64","year":"2025","journal-title":"Rheumatol. Oxf. Engl"},{"key":"2026010906200670000_2026.01.06.26343530v1.32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12964-021-00751-w","article-title":"Regulation of exosome secretion by cellular retinoic acid binding protein 1 contributes to systemic anti-inflammation","volume":"19","year":"2021","journal-title":"Cell Commun. Signal. CCS"},{"key":"2026010906200670000_2026.01.06.26343530v1.33","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1002\/cpt.3624","article-title":"SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity Study","volume":"117","year":"2025","journal-title":"Clin. Pharmacol. Ther"},{"key":"2026010906200670000_2026.01.06.26343530v1.34","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cpt.70012","article-title":"Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity","volume":"118","year":"2025","journal-title":"Clin. Pharmacol. Ther"},{"key":"2026010906200670000_2026.01.06.26343530v1.35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0733-8627(20)30236-4","article-title":"Electrolyte abnormalities in the alcoholic patient","volume":"8","year":"1990","journal-title":"Emerg. Med. Clin. North Am"},{"key":"2026010906200670000_2026.01.06.26343530v1.36","first-page":"7","article-title":"[Alcohol-dependent mast cell activation in ulcer]","volume":"39","year":"1993","journal-title":"Minerva Gastroenterol. Dietol"},{"key":"2026010906200670000_2026.01.06.26343530v1.37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/SHK.0000000000000265","article-title":"Alcohol potentiates postburn remote organ damage through shifts in fluid compartments mediated by bradykinin","volume":"43","year":"2015","journal-title":"Shock Augusta Ga"},{"key":"2026010906200670000_2026.01.06.26343530v1.38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jdcr.2019.11.013","article-title":"Segmental urticaria triggered by alcohol consumption","volume":"6","year":"2020","journal-title":"JAAD Case Rep"},{"key":"2026010906200670000_2026.01.06.26343530v1.39","doi-asserted-by":"crossref","first-page":"G66","DOI":"10.1152\/ajpgi.00334.2017","article-title":"Complement Factor D protects mice from ethanol-induced inflammation and liver injury","volume":"315","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol"},{"key":"2026010906200670000_2026.01.06.26343530v1.40","first-page":"1365","article-title":"Interplay between acetylation and ubiquitination controls PSAT1 protein stability in lung adenocarcinoma. Commun","volume":"7","year":"2024","journal-title":"Biol"},{"key":"2026010906200670000_2026.01.06.26343530v1.41","doi-asserted-by":"crossref","first-page":"11137","DOI":"10.1038\/s41598-021-90086-w","article-title":"Macrophages rely on extracellular serine to suppress aberrant cytokine production","volume":"11","year":"2021","journal-title":"Sci. Rep"},{"key":"2026010906200670000_2026.01.06.26343530v1.42","first-page":"A4147849","article-title":"Abstract 4147849: Extracellular Transcriptomics-driven Identification and Characterization of lncRNA LINC00989 in Heart Failure Progression","volume":"150","year":"2024","journal-title":"Circulation"},{"key":"2026010906200670000_2026.01.06.26343530v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.02.048"},{"key":"2026010906200670000_2026.01.06.26343530v1.44","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/s41588-025-02395-9","article-title":"Recommendations for responsible use of population descriptors in polygenic risk score development","volume":"57","year":"2025","journal-title":"Nat. Genet"},{"key":"2026010906200670000_2026.01.06.26343530v1.45","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/22.172"},{"key":"2026010906200670000_2026.01.06.26343530v1.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2011.08.007"},{"key":"2026010906200670000_2026.01.06.26343530v1.47","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.115.178905"},{"key":"2026010906200670000_2026.01.06.26343530v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0064-5"},{"key":"2026010906200670000_2026.01.06.26343530v1.49","unstructured":"Curated Data Repository (CDR) version 8 Release Notes. All of Us Research Hub https:\/\/support.researchallofus.org\/hc\/en-us\/articles\/30294451486356-Curated-Data-Repository-CDR-version-8-Release-Notes (2025)."},{"key":"2026010906200670000_2026.01.06.26343530v1.50","first-page":"385","article-title":"Veterans Health Information Exchange: Successes and Challenges of Nationwide Interoperability","volume":"2018","year":"2018","journal-title":"AMIA Annu. Symp. Proc. AMIA Symp"},{"key":"2026010906200670000_2026.01.06.26343530v1.51","doi-asserted-by":"publisher","DOI":"10.1097\/NAQ.0000000000000118"},{"key":"2026010906200670000_2026.01.06.26343530v1.52","doi-asserted-by":"publisher","DOI":"10.1186\/s40246-023-00487-3"},{"key":"2026010906200670000_2026.01.06.26343530v1.53","unstructured":"Discover MVP Data. VA | Million Veteran Program https:\/\/www.mvp.va.gov\/pwa\/discover-mvp-data."},{"key":"2026010906200670000_2026.01.06.26343530v1.54","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01891-3"},{"key":"2026010906200670000_2026.01.06.26343530v1.55","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamainternmed.34"},{"key":"2026010906200670000_2026.01.06.26343530v1.56","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1002\/pds.5361","article-title":"Physician adjudication of angioedema diagnosis codes in a population of patients with heart failure prescribed angiotensin-converting enzyme inhibitor therapy","volume":"30","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"2026010906200670000_2026.01.06.26343530v1.57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/20009666.2020.1711641","article-title":"ACE inhibitor angioedema: characterization and treatment versus non-ACE angioedema in acute hospitalized patients","volume":"10","year":"2020","journal-title":"J. Community Hosp. Intern. Med. Perspect"},{"key":"2026010906200670000_2026.01.06.26343530v1.58","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31829b1d2a"},{"key":"2026010906200670000_2026.01.06.26343530v1.59","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5547"},{"key":"2026010906200670000_2026.01.06.26343530v1.60","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(22)01841-4","article-title":"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study","volume":"401","year":"2023","journal-title":"Lancet Lond. Engl"},{"key":"2026010906200670000_2026.01.06.26343530v1.61","unstructured":"National Academies of Sciences, Engineering, and Medicine; Division of Behavioral and Social Sciences and Education; Health and Medicine Division; Committee on Population; Board on Health Sciences Policy; Committee on the Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field. (National Academies Press (US), Washington (DC), 2023)."},{"key":"2026010906200670000_2026.01.06.26343530v1.62","first-page":"e1916641","article-title":"Association of Dietary Patterns in Midlife and Cognitive Function in Later Life in US Adults Without Dementia. JAMA Netw","volume":"2","year":"2019","journal-title":"Open"},{"key":"2026010906200670000_2026.01.06.26343530v1.63","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0184-y"},{"key":"2026010906200670000_2026.01.06.26343530v1.64","doi-asserted-by":"publisher","DOI":"10.1126\/science.273.5281.1516"},{"key":"2026010906200670000_2026.01.06.26343530v1.65","doi-asserted-by":"publisher","DOI":"10.1086\/519795"},{"key":"2026010906200670000_2026.01.06.26343530v1.66","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12874-020-01137-1","article-title":"Estimation in meta-analyses of response ratios","volume":"20","year":"2020","journal-title":"BMC Med. Res. Methodol"},{"key":"2026010906200670000_2026.01.06.26343530v1.67","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giz082"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.01.06.26343530","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:20:17Z","timestamp":1767968417000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.64898\/2026.01.06.26343530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":67,"URL":"https:\/\/doi.org\/10.64898\/2026.01.06.26343530","relation":{},"subject":[],"published":{"date-parts":[[2026,1,8]]},"subtype":"preprint"}}